A Study to Evaluate the Safety of a Single Intravenous (IV) Dose of Orbactiv (Oritavancin) in Participants on Chronic Warfarin Therapy Being Treated For Acute Bacterial Skin and Skin Structure Infection (ABSSSI)

Inclusion Criteria: * Diagnosis of ABSSSI (wound infection, cellulitis/erysipelas, or cutaneous abscess) suspected or confirmed to be caused by a Gram-positive pathogen requiring IV therapy * Must be currently being treated with chronic warfarin therapy\* \*Participants in the non-warfarin group are not required to be on chronic warfarin therapy. Exclusion Criteria: * Known or suspected bacteremia, sepsis or refractory shock * Participants who are likely to need treatment with IV heparin within 48 hours * Significant or life-threatening condition * Women who are pregnant or nursing * Receiving chronic systemic immunosuppressive therapy such as chemotherapy or prednisone * CD4 count \<200 cells/mm\^3 in participants with known human immunodeficiency virus or acquired immune deficiency syndrome * Neutropenia